Pegunigalsidase alfa (Protalix Biotherapeutics)

Product Name :
Pegunigalsidase alfa (Protalix Biotherapeutics)

Search keywords :
Alpha-Gal

drugId :
null

Target Vo:
Glycogen

Target Vo Short Name :
Glycogen

Moa_Name:
α-Galactosidase replacements

First Approval Country :
EU

First Approval Date Filter:
2023

Origin Company_Name :
Protalix Biotherapeutics Inc

Active Company_Name :
Chiesi Farmaceutici SPA

Active Indication_Name:
Fabry Disease

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
GPR43 Antibody manufacturer
Itepekimab NF-κB
Notch 1 Antibody: Notch 1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 125 kDa, targeting to Notch 1. It can be used for WB,ICC/IF,IHC-P,IP,FC assays with tag free, in the background of Human, Mouse.

Author: Betaine hydrochloride

Related Posts